Urogen Pharma Ltd.
A biotech whose gel turns liquid to jelly at body heat, letting cancer drugs linger in the urinary tract for hours instead of minutes. Its FDA-approved treatments Jelmyto and Zusduri offer non-surgical options for rare bladder and kidney-tube cancers. Born in 2004 as Theracoat, it renamed itself UroGen in 2015 and won its first approval in 2020.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| The Toronto-Dominion Bank | 13G/APassive | 6.7% | 3.27M | Aug 12, 2026 |
| TD SECURITIES INC. | 13G/APassive | 0.2% | 101.3K | Aug 12, 2026 |
| Paradigm BioCapital Advisors LP | 13G/APassive | 3.5% | 1.70M | May 15, 2026 |
| Paradigm BioCapital Advisors GP LLC | 13G/APassive | 3.5% | 1.70M | May 15, 2026 |
| Senai Asefaw, M.D. | 13G/APassive | 3.5% | 1.70M | May 15, 2026 |
| Paradigm BioCapital International Fund Ltd. | 13G/APassive | 3.1% | 1.50M | May 15, 2026 |
| BlackRock, Inc. | 13GPassive | 5.2% | 2.52M | Apr 27, 2026 |
| Cowen Financial Products LLC | 13G/APassive | 0% | 0 | Nov 14, 2025 |
| RA Capital Management, L.P. | 13G/APassive | 0% | 0 | Aug 14, 2025 |
| Peter Kolchinsky | 13G/APassive | 0% | 0 | Aug 14, 2025 |